Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3223482 | 0.86 | MEN1 (0.32) | MEN1KMT2AKDM4ERCE1ALDH1A1 | |
| SCHEMBL29171497 | 0.75 | KMT2A (0.33) | MEN1KMT2A | |
| SCHEMBL4373398 | 0.70 | ALDH1A1 (0.35) | MEN1KMT2AKDM4ERCE1ALDH1A1 | |
| SCHEMBL5611105 | 0.70 | — | — | |
| SCHEMBL7949122 | 0.65 | APAF1 (0.33) | ALDH1A1MAPTHTTLMNA | |
| SCHEMBL6465444 | 0.63 | BCHE (0.31) | KMT2A | |
| SCHEMBL3221291 | 0.62 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL7950425 | 0.62 | KMT2A (0.31) | KMT2A | |
| SCHEMBL6467713 | 0.62 | BCHE (0.32) | — | |
| SCHEMBL7950488 | 0.61 | GAA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381618-B1 | PROCESS FOR THE PRODUCTION OF MONOHALIDE OR DIHALIDE METALLOCENE COMPOUNDS | BASELL POLYOLEFINE GMBH (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-7115761-B2 | Process for the production of monohalide or dihalide metallocene compounds | BASELL POLYOLEFINE GMBH (DE) | 2006-10-03 | — | — | US | disclosed |
| US-20060025621-A1 | Process for the production of monohalide or dihalide metallocene compounds | BASELL POLYOLEFINE GMBH (DE) | 2006-02-02 | — | — | US | disclosed |
| US-6987196-B2 | Process for the production of monohalide or dihalide metallocene compounds | BASELL POLYOLEFINE GMBH (DE) | 2006-01-17 | — | — | US | disclosed |
| US-20040147770-A1 | Process for the production of monohalide or dihalide metallocene compounds | EQUISTAR CHEMICALS, LP | 2004-07-29 | — | — | US | disclosed |
| EP-1381618-A2 | PROCESS FOR THE PRODUCTION OF MONOHALIDE OR DIHALIDE METALLOCENE COMPOUNDS | Basell Polyolefine GmbH (DE) | 2004-01-21 | — | — | EP | disclosed |
| WO-2002083699-A2 | PROCESS FOR THE PRODUCTION OF MONOHALIDE OR DIHALIDE METALLOCENE COMPOUNDS | BASELL POLYOLEFINE GMBH (DE) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025621-A1 | Process for the production of monohalide or dihalide metallocene compounds | SOD1, HAO2, HMOX2 | MEN1 2535/4885KMT2A 705/4885KDM4E 4456/4885 |
| US-20040147770-A1 | Process for the production of monohalide or dihalide metallocene compounds | SOD1, HAO2, MT-CO1 | MEN1 2983/4885KMT2A 577/4885KDM4E 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.